Compare AROC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROC | KYMR |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.8B |
| IPO Year | 2007 | 2020 |
| Metric | AROC | KYMR |
|---|---|---|
| Price | $37.50 | $84.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 26 |
| Target Price | $40.00 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 1.3M | 507.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 74.29 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $1,489,818,000.00 | $39,211,000.00 |
| Revenue This Year | $7.06 | $10.61 |
| Revenue Next Year | $5.27 | $8.17 |
| P/E Ratio | $19.71 | ★ N/A |
| Revenue Growth | ★ 28.70 | N/A |
| 52 Week Low | $21.17 | $28.06 |
| 52 Week High | $37.73 | $103.00 |
| Indicator | AROC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 48.45 |
| Support Level | $34.30 | $77.78 |
| Resistance Level | N/A | $90.15 |
| Average True Range (ATR) | 1.07 | 3.06 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 92.94 | 29.50 |
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.